Compound News and Research

RSS

Senhwa Biosciences raises additional $17 million USD in Series B financing

Senhwa Biosciences, Inc. has raised an additional $17 million USD in a Series B financing to drive its anticancer agents through critical clinical trials, the company announced today.

12 Dec 2013

Late-breaking abstracts on treatment of blood cancers and bleeding disorders presented at ASH meeting

A range of studies highlighting late-breaking research advances in the understanding and treatment of blood cancers and bleeding disorders are being presented today during the 55th American Society of Hematology Annual Meeting and Exposition in New Orleans.

12 Dec 2013

Emergent BioSolutions enters into definitive agreement to acquire Cangene

Emergent BioSolutions Inc.announced that it has entered into a definitive agreement with Cangene Corporation (TSX: CNJ) under which Emergent will acquire all of the outstanding common shares of Cangene in an all-cash transaction valued at $3.24 per share on a fully diluted basis for an aggregate purchase price of $222 million.

12 Dec 2013

Pfizer, Octapharma AG to market investigational agent for urgent reversal of vitamin K antagonist

...

11 Dec 2013

Experimental compound reduces joint inflammation in animal models of rheumatoid arthritis

An experimental compound synthesized and developed by scientists from the Florida campus of The Scripps Research Institute has the capacity to significantly reduce joint inflammation in animal models of rheumatoid arthritis, an autoimmune disease that affects more than two million Americans.

11 Dec 2013

Antibody-toxin compound shows compelling antitumor activity in non-Hodgkin lymphomas patients

A toxin linked to a targeted monoclonal antibody has shown "compelling" antitumor activity in patients with non-Hodgkin lymphomas who were no longer responding to treatment, according to a report from Dana-Farber Cancer Institute.

11 Dec 2013

Beta-carotene: An important and safe precursor for vitamin A

A Case Western Reserve University School of Medicine study in the November 22 issue of Journal of Biological Chemistry, explains how vitamin A is generated from beta carotene, its dietary precursors. The discovery sheds new light into how beta carotene’s enzymes are utilized differently contributing to the vitamin’s production. This insight will help guide solutions for vitamin A deficiency, a global public health problem affecting more than half of all countries, according to the World Health Organization.

11 Dec 2013

Biosimulation and epilepsy treatments: an interview with Dr. Serge Bischoff, CEO of Rhenovia and RHENEPI program director

The need for biosimulation is primarily to do with the very high attrition rate in drug development and especially in the development of drugs for the central nervous system.

10 Dec 2013

ImmunoGen presents Phase I trial results of SAR650984 at ASH annual meeting

ImmunoGen, Inc., a biotechnology company that develops targeted, antibody-based anticancer therapeutics, today announced the first clinical findings with SAR650984 reported in an oral presentation at the ASH annual meeting. The data are from an ongoing Phase I trial assessing this CD38-targeting therapeutic antibody in patients with CD38-positive MM or other hematologic malignancy.

10 Dec 2013

IBN and IBM discover new medical application for converted PET bottles

Researchers at Singapore's Institute of Bioengineering and Nanotechnology (IBN) and California's IBM Research - Almaden (IBM) have discovered a new, potentially life-saving application for polyethylene terephthalate (PET), which is widely used to make plastic bottles.

10 Dec 2013

Penn researchers identify protein that could clear Alzheimer's plaques

The body is structured to ensure that any invading organisms have a tough time reaching the brain, an organ obviously critical to survival. Known as the blood-brain barrier, cells that line the brain and spinal cord are tightly packed, making it difficult for anything besides very small molecules to cross from the bloodstream into the central nervous system. While beneficial, this blockade also stands in the way of delivering drugs intended to treat neurological disorders, such as Alzheimer's.

9 Dec 2013

Gemtuzumab with standard chemotherapy can reduce risk of relapse in pediatric patients with AML

The addition of a monoclonal antibody called gemtuzumab combined with standard chemotherapy has been shown to significantly reduce the risk of relapse and increase rates of disease-free survival in pediatric patients with acute myeloid leukemia (AML).

9 Dec 2013

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Janssen Research & Development, LLC today announced positive results from a pivotal Phase 2 global registration study (MCD2001) suggesting siltuximab, an investigational compound, along with best supportive care, exhibited statistically significant efficacy and a tolerable safety profile compared with placebo and BSC in treating patients with the rare disorder Multicentric Castleman's Disease who are HIV-negative and human herpes virus 8-negative.

8 Dec 2013

Ancon Technologies unveils new cancer-screening device

Ancon Technologies, a company devoted to finding new ways to beat cancer, recently unveiled a new cancer-screening device to the public, the NBT detector. The company's latest product aims to bring cancer detection to the next level: it uses Nanoparticle Biomarker Tagging technology to identify cancer biomarkers in exhaled air.

6 Dec 2013

Emids Technologies announces joint investment of $13.3M by Baird Capital and Council Capital

emids Technologies announced today a joint investment of $13.3 million by Baird Capital's venture capital group of Chicago and Nashville, Tenn.-based Council Capital that will enable the company to build on its leading position in the provision of healthcare IT services and solutions.

6 Dec 2013

Innovative DNA engineering technique discovers potential functions hidden within bacterial genomes

A group of University of Illinois researchers, led by Centennial Chair Professor of the Department of Chemical and Biomolecular Engineering Huimin Zhao, has demonstrated the use of an innovative DNA engineering technique to discover potentially valuable functions hidden within bacterial genomes.

6 Dec 2013

AtheroNova completes active treatment portion of Phase 1 clinical trial with AHRO-001

AtheroNova Inc., a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announces achievement of a major milestone with the completion of the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The Phase 1 study objective is to evaluate the safety, tolerability and pharmacokinetics of AHRO-001 in healthy volunteers. The clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

5 Dec 2013

B2G2 component of grape seed extract induces apoptosis in prostate cancer cells

A University of Colorado Cancer Center study published online ahead of print in the journal Nutrition and Cancer describes the laboratory synthesis of the most active component of grape seed extract, B2G2, and shows this synthesized compound induces the cell death known as apoptosis in prostate cancer cells while leaving healthy cells unharmed.

5 Dec 2013

Enrollment opens for IMO-8400 Phase 1/2 trial in patients with Waldenström's macroglobulinemia

Idera Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing a novel therapeutic approach for the treatment of autoimmune diseases and genetically defined forms of B-cell lymphoma, today announced that enrollment is open for a Phase 1/2 clinical trial of IMO-8400 in patients with Waldenström's macroglobulinemia, following acceptance of its Investigational New Drug application by the U.S. Food and Drug Administration.

5 Dec 2013

New research offers fresh insights to drug designers searching for better pain treatments

In a technical tour de force, UC San Francisco scientists have determined, at near-atomic resolution, the structure of a protein that plays a central role in the perception of pain and heat.

5 Dec 2013

Compound News and Research

Senhwa Biosciences raises additional $17 million USD in Series B financing

Late-breaking abstracts on treatment of blood cancers and bleeding disorders presented at ASH meeting

Emergent BioSolutions enters into definitive agreement to acquire Cangene

Pfizer, Octapharma AG to market investigational agent for urgent reversal of vitamin K antagonist

Experimental compound reduces joint inflammation in animal models of rheumatoid arthritis

Antibody-toxin compound shows compelling antitumor activity in non-Hodgkin lymphomas patients

Beta-carotene: An important and safe precursor for vitamin A

Biosimulation and epilepsy treatments: an interview with Dr. Serge Bischoff, CEO of Rhenovia and RHENEPI program director

ImmunoGen presents Phase I trial results of SAR650984 at ASH annual meeting

IBN and IBM discover new medical application for converted PET bottles

Penn researchers identify protein that could clear Alzheimer's plaques

Gemtuzumab with standard chemotherapy can reduce risk of relapse in pediatric patients with AML

Janssen reports positive pivotal Phase 2 study data of siltuximab for Multicentric Castleman's Disease

Ancon Technologies unveils new cancer-screening device

Emids Technologies announces joint investment of $13.3M by Baird Capital and Council Capital

Innovative DNA engineering technique discovers potential functions hidden within bacterial genomes

AtheroNova completes active treatment portion of Phase 1 clinical trial with AHRO-001

B2G2 component of grape seed extract induces apoptosis in prostate cancer cells

Enrollment opens for IMO-8400 Phase 1/2 trial in patients with Waldenström's macroglobulinemia

New research offers fresh insights to drug designers searching for better pain treatments

Advancing therapeutic biopolymer development eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News